The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

Scott L. Burrows net worth and biography

Scott Burrows Biography and Net Worth

CFO of Arcutis Biotherapeutics

Prior to becoming chief financial officer in April 2021, Mr Burrows served as Arcutis’ vice president of finance since joining the Company in May 2019. Prior to Arcutis, Mr Burrows was the head of international investor relations for Shire, plc in Zug, Switzerland, where he played a key role in gathering European and Japanese investor support for Takeda’s acquisition of Shire. Prior to Shire, he spent 15 years at Amgen, Inc. in roles of increasing responsibility across financial planning and analysis, treasury, and investor relations. Mr Burrows started his career as a consultant at Arthur Andersen. He earned both his BA and MBA from the University of California, Los Angeles, and is a licensed CPA in California (inactive).

What is Scott L. Burrows' net worth?: The estimated net worth of Scott L. Burrows is at least $517,256.25 as of March 6th, 2023. Mr. Burrows owns 59,115 shares of Arcutis Biotherapeutics stock worth more than $517,256 as of April 25th. This net worth evaluation does not reflect any other assets that Mr. Burrows may own. Learn More about Scott L. Burrows' net worth.
How do I contact Scott L. Burrows?: The corporate mailing address for Mr. Burrows and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at [email protected]. Learn More on Scott L. Burrows' contact information.
Has Scott L. Burrows been buying or selling shares of Arcutis Biotherapeutics?: Scott L. Burrows has not been actively trading shares of Arcutis Biotherapeutics in the last ninety days. Most recently, Scott L. Burrows sold 291 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $15.26, for a transaction totalling $4,440.66. Following the completion of the sale, the chief financial officer now directly owns 59,115 shares of the company's stock, valued at $902,094.90. Learn More on Scott L. Burrows' trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Patricia Turney (SVP), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, Arcutis Biotherapeutics insiders bought shares 1 times. They purchased a total of 80,000 shares worth more than $200,000.00. During the last year, insiders at the sold shares 5 times. They sold a total of 10,370 shares worth more than $75,737.90. The most recent insider tranaction occured on March, 4th when insider Masaru Matsuda sold 3,760 shares worth more than $41,811.20. Insiders at Arcutis Biotherapeutics own 20.7% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 3/4/2024.

Scott L. Burrows Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2023	Sell	291	$15.26	$4,440.66	59,115
3/2/2023	Sell	1,434	$15.83	$22,700.22	38,406
2/28/2023	Sell	416	$16.17	$6,726.72	39,840
3/7/2022	Sell	10	$16.44	$164.40
3/4/2022	Sell	293	$16.86	$4,939.98
12/27/2021	Sell	12,560	$20.07	$252,079.20

Scott L. Burrows Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $8.75

$8.74

$9.10

50 Day Range

MA: $10.14

$7.58

$12.53

2 Week Range

Now: $8.75

$1.76

$15.21

Volume

1,792,516 shs

Average Volume

4,657,915 shs

Market Capitalization

$847.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14